Clinical trials: Cat Allergy
Cat Allergy, Rhinoconjunctivitis
An Optional Two Year Follow Up Study to Study CP005A
Cat allergy is an increasingly prevalent condition affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT01604018
- Where
- Canada
- Volunteers
- 51 people
- Sponsor
- Circassia Limited
Asthma
A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma
This was a 3-center, randomized, double-blind, parallel-group, placebo-controlled study with a 16-week treatment phase to determine whether subcutaneous omalizumab, compared with placebo, reduces the degree of bronchoconstriction…
- Trial name
- AERO (NCT00495612)
- Testing
- Omalizumab
- Volunteers
- 69 people
- Sponsor
- Genentech, Inc.
Rhinitis, Allergic
Ability of a Cat Food to Reduce Respiratory Symptoms in Cat Allergic Patients
Cat allergy is the most common animal allergy, affecting approximately 1 in 5 adults worldwide. The prevalence of allergy to furry animals is increasing, and cat allergy is a major risk factor for the development of asthma and…
- Trial name
- CATS (NCT05656482)
- Testing
- Cats fed with PRO PLAN® LIVECLEAT®
- Where
- France
- Volunteers
- 50 people
- Sponsor
- MASK-air SAS
Perennial Allergy to House Dust Mite and/or Cat
Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
The purpose of the study is to test the efficacy of a vaccine against house dust mite and/or cat allergy compared to placebo in adult patients.
- Trial name
- NCT00575003
- Testing
- CYT003-QbG10
- Where
- 7 sites in Estonia, Latvia and 1 more
- Volunteers
- 64 people
- Sponsor
- Cytos Biotechnology AG
Cat Allergy
Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT00729508
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Circassia Limited
Allergy Testing, Peanut Allergies
BÜHLMANN BAT (Basophil Activation Test) in Allergy Diagnosis (Exploratory Pilot Study)
The goal of this exploratory pilot study is to generate early data needed for future validation studies of the automated BÜHLMANN BAT (Basophil activation test) assay.
- Conditions
- Allergy Testing, Peanut Allergies, Venom Allergy, House Dust Mite Allergy
- Trial name
- NCT07596303
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Bühlmann Laboratories AG
Allergy to Cats, Allergic Rhinoconjunctivitis
Effect of holoBLG on Cat Allergic Patients
The aim of the study is to investigate the antigen-unspecific effect of a 3 months supplementation with a food for special medical purposes (FSMP) in form of a lozenge containing beta-lactoglobulin (BLG), iron, retinoic acid…
- Trial name
- NCT05455749
- Testing
- holoBLG
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Allergy Therapeutics
Cat Allergy
Phase III Cat-PAD Follow-on Study
The purpose of this study is to evaluate the continued effectiveness and safety of Cat-PAD in cat allergic subjects for up to five years after the start of administration of treatment.
- Trial name
- NCT02040844
- Testing
- Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762], Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762], Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]
- Volunteers
- 430 people
- Sponsor
- Circassia Limited
Cat Induced Allergic Rhinitis
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms
This is a single-center, prospective, randomized, double-blind, placebo-controlled, two-way crossover study. A live cat challenge model will be used for exposing subjects to Fel d1.
- Trial name
- NCT00637884
- Testing
- Fexofenadine HCl
- Volunteers
- 70 people
- Sponsor
- Sanofi
Cat Allergy
Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis. Cat-PAD is a novel, synthetic, allergen derived peptide desensitising vaccine currently being developed for…
- Trial name
- NCT01383603
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Circassia Limited
Asthma, Allergy
Efficacy of Air Cleaners in Asthmatics Allergic to Cat in ALYATEC Environmental Exposure Chamber
The aim of this study is to determine the efficacy of Rowenta® "Intense Pure Air XL" air cleaner on the early and late bronchial response, in cat-allergic asthmatic patients during an allergen exposure in ALYATEC environmental…
- Trial name
- NCT03928561
- Testing
- Active intense Pure Air XL air cleaner
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Alyatec
Cat Allergy
Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis. Cat-PAD is a novel synthetic, allergen derived peptide desensitizing vaccine currently being developed for the…
- Trial name
- NCT01383590
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Circassia Limited
Allergy and Immunology
Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects
This is a single-center, randomized, double-blind, placebo-controlled, single-dose, dose- escalation study in otherwise healthy cat-, dust mite-, or Bermuda grass-allergic male and female subjects.
- Trial name
- NCT02559258
- Where
- Australia
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Tunitas Therapeutics, Inc.
Cat Allergy
Cat-PAD Exposure Chamber Study
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT01033344
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 210 people
- Sponsor
- Circassia Limited
Rhinoconjunctivitis
Paediatric Safety Study in Cat-PAD
Study to Assess the Safety of Cat-PAD in Cat Allergic Paediatric Subjects
- Trial name
- NCT01921257
- Testing
- Cat-PAD
- Where
- 3 sites in Poland
- Volunteers
- 16 people
- Sponsor
- Circassia Limited
Cat Allergy
Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT00867906
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Circassia Limited
Allergy, Allergic Asthma
abioSCOPE IgE Assay to Aid in the Diagnosis of Allergies
This is a multicenter, prospective, observational study designed to determine the clinical sensitivity and specificity of the Abionic IVD CAPSULE Allergic Asthma panel performed on Abionic's abioSCOPE device using K3-EDTA…
- Conditions
- Allergy, Allergic Asthma, Allergy to Cats, Allergy to House Dust
- Trial name
- NCT04442932
- Testing
- Blood Collection
- Where
- 5 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Abionic SA
Cat Allergy
Safety of Cat-PAD in Cat Allergic Subjects
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT00685711
- Testing
- Cat-PAD
- Where
- Germany
- Volunteers
- 88 people
- Sponsor
- Circassia Limited
Cat Allergy, Rhinoconjunctivitis
Cat-PAD Follow on Study
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT01272323
- Testing
- Cat-PAD Dose 1, Cat-PAD Dose 2
- Where
- Canada
- Volunteers
- 170 people
- Sponsor
- Circassia Limited
Birch Pollen Allergy, Grass Pollen Allergy
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
About 20% of the general population are affected by an allergy - with an upward trend. Quite often, allergic people do not consider their disease as serious and suffer from subsequent complications, like allergic asthma, later in…
- Conditions
- Birch Pollen Allergy, Grass Pollen Allergy, House Dust Mite Allergy, Cat Allergy
- Trial name
- MADMAX (NCT04435678)
- Testing
- ALEX² test using the MAX 45k automated laboratory system
- Where
- 2 sites in Austria
- Volunteers
- 839 people
- Sponsor
- MacroArray Diagnostics GmbH